Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04355169 · ClinicalTrials.gov registry record · Phase 2
A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection
A Phase 2 study, sponsored by Shionogi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04355169 is a Phase 2 study that was terminated before completion, run by Shionogi. The registered enrollment target is 2 participants.
The verdict
NCT04355169, a Phase 2 study, was terminated before completion, sponsored by Shionogi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The objective of this study is to compare the efficacy of naldemedine versus placebo and to assess its effect on the time to gastrointestinal (GI) recovery following surgeries that include bowel resection and bowel transection.
Interventions
- DRUG Placebo
- DRUG Naldemedine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2021-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04355169
The ClinicalTrials.gov registry entry for NCT04355169 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04355169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04355169 about?
NCT04355169 is a clinical study titled "A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection". The objective of this study is to compare the efficacy of naldemedine versus placebo and to assess its effect on the time to gastrointestinal (GI) recovery following surgeries that include bowel resection and bowel transection.
What is the current status of trial NCT04355169?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-11-06. Estimated completion is 2021-01-04.
What interventions are being tested in trial NCT04355169?
The interventions under investigation include: Placebo (DRUG), Naldemedine (DRUG).
Who is sponsoring clinical trial NCT04355169?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.